Non-familial cardiomyopathies in Lebanon: exome sequencing results for five idiopathic cases

Marwan M. RefaatEmail author View ORCID ID profile,
Sylvana Hassanieh,
Jad A. Ballout,
Patrick Zakka,
Mostafa Hotait,
Athar Khalil,
Fadi Bitar,
Mariam Arabi,
Samir Arnaout,
Hadi Skouri,
Antoine Abchee,
Bernard Abi-Saleh,
Maurice Khoury,
Andreas Massouras and
Georges Nemer

BMC Medical Genomics201912:33

https://doi.org/10.1186/s12920-019-0478-7

Received: 6 May 2018
Accepted: 29 January 2019
Published: 14 February 2019

Open Peer Review reports

Abstract

Background

Cardiomyopathies affect more than 0.5% of the general population. They are associated with high risk of sudden cardiac death, which can result from either heart failure or electrical abnormalities. Although different mechanisms underlie the various types of cardiomyopathies, a principal pathology is common to all and is usually at the level of the cardiac muscle. With a relatively high incidence rate in most countries, and a subsequent major health burden on both the families and governments, cardiomyopathies are gaining more attention by researchers and pharmaceutical companies as well as health government bodies. In Lebanon, there is no official data about the spectrum of the diseases in terms of their respective prevalence, clinical, or genetic profiles.

Methods

We used exome sequencing to unravel the genetic basis of idiopathic cases of cardiomyopathies in Lebanon, a relatively small country with high rates of consanguineous marriages.

Results

Five cases were diagnosed with different forms of cardiomyopathies, and exome sequencing revealed the presence of already documented or novel mutations in known genes in three cases: LMNA for an Emery Dreifuss Muscular Dystrophy case, PKP2 for an arrhythmogenic right ventricle dysplasia case, and MYPN for a dilated cardiomyopathy case. Interestingly two brothers with hypertrophic cardiomyopathy have a novel missense variation in NPR1, the gene encoding the natriuretic peptides receptor type I, not reported previously to be causing cardiomyopathies.

Conclusion

Our results unravel novel mutations in known genes implicated in cardiomyopathies in Lebanon. Changes in clinical management however, require genetic profiling of a larger cohort of patients.